Sorafenib is the first systemic agent approved for treating HCC and is a multikinase inhibitor with activity against VEGFR2, PDGFR, c-Kit receptor, b-RAF, and p38 [39], which are signal transduction pathways that may be involved in the pathogenesis of HCC [40]. Here, PDGFRB is linked to hepatocellular carcinoma.